FindMyKOL
Clinical trialNCT01778530TerminatedPhase 2Interventional

TRC105 for Recurrent Glioblastoma

NCT01778530 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). As of 21 Nov 2026, it was terminated. It studies TRC105 in Glioblastoma Multiforme. The registry lists an enrollment of 2 participants at 1 site in 1 country. The registry lists a start date of 31 Dec 2012 and a primary completion date of 28 Feb 2014.

SponsorNational Cancer Institute (NCI) →Enrollment2Glioblastoma Multiforme
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01778530
FieldValue
Registry IDNCT01778530
StatusTerminated
PhasePhase 2
Study typeInterventional trial
Lead sponsorNational Cancer Institute (NCI)
Enrollment2
Registered sites1
Countries1
ConditionsGlioblastoma Multiforme
DrugsTRC105
Start31 Dec 2012
Primary completion28 Feb 2014
Study completion28 Feb 2014
Last update posted7 Oct 2015

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Background: \- Glioblastoma is an aggressive type of brain cancer that often resists treatment. TRC105 is an experimental drug that blocks the growth of new blood vessels. It is being studied for possible use in treating different kinds of cancer. Researchers want to see if TRC105 can be used to treat glioblastoma that has not responded to standard treatments. Objectives: \- To test the safety and effectiveness of TRC105 in adults who have glioblastoma that has not responded to standard treatments. Eligibility: \- Individuals at least 18 years of age who have glioblastoma that has not responded to standard treatments. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and other tests will be used to study the tumor before the start of treatment. * Participants will have 28-day (4-week) cycles of treatment. * Participants will have TRC105 intravenously once a week. The first infusion will take about 4 hours. The length of time needed for the infusion may be slowly reduced if it is well tolerated. * At the end of the first cycle (the first 4 weeks), the imaging studies will be repeated before continuing TRC105. * Participants will take TRC105 for as long as the tumor does not grow and the side effects are not too severe. They will have imaging studies at the end of every cycle to evaluate the tumor.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Maryland, United States1 site
  • National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 siteMD1DelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

TRC105
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT01778530

Each answer restates registry values shown on this page.

What is NCT01778530?

NCT01778530 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). It studies TRC105 in Glioblastoma Multiforme.

Who leads NCT01778530?

The registry names Joohee Sul, M.D. (principal investigator, National Cancer Institute (NCI)) as the overall official.

Where does NCT01778530 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT01778530 study?

The registered drug and biological interventions are TRC105.

When did NCT01778530 end?

The registry lists a primary completion date of 28 Feb 2014 and a study completion date of 28 Feb 2014. The sponsor last updated the record on 7 Oct 2015.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.